Immunohistochemistry Market: Information by Product (Antibodies, Reagents, Equipment, Kit), Application (Diagnostics, Drug Development, and Testing), and Region—Forecast till 2029

Feb 09, 2021   Immunohistochemistry (IHC) is a technique used to visualize and locate specific antigens in a tissue sample using antibodies conjugated to enzymes that catalyze reactions to form detectable compounds. The IHC methodology has undergone rapid transformative growth to cope with the growing demand for detailed and reliable data, leading to the emergence of sophisticated modifications that can collect more qualitative details.  The global immunohistochemistry market was estimated at USD 1,800 m...
Request Free Sample Report

Report Description

Immunohistochemistry (IHC) is a technique used to visualize and locate specific antigens in a tissue sample using antibodies conjugated to enzymes that catalyze reactions to form detectable compounds. The IHC methodology has undergone rapid transformative growth to cope with the growing demand for detailed and reliable data, leading to the emergence of sophisticated modifications that can collect more qualitative details. 

The global immunohistochemistry market was estimated at USD 1,800 million in 2019 and is expected to grow at a 6.58% CAGR during the forecast period.

Immunohistochemistry-Market

RisingIncidence and Prevalence of Cancer

Cancer is a public health burden, and the prevalence of cancer has grown exponentially globally across the years. According to the World Health Organization (WHO), cancer is the 2nd leading cause of death worldwide. It further states that an estimated 9.6 million death, i.e., in 2018, 1 in 6 deaths were reported due to cancer. As per GLOBOCAN, the prevalence of cancer was 43.8 million worldwide in 2018, and 9.6 million cancer deaths were registered in the same year.

In recent times, IHC has been most widely employed in oncology research to examine the cancer proteome. The key diagnostic applications of IHC include differentiating invasive carcinoma from pseudo-invasive lesions, normal ductal hyperplasia (UDH) from atypical ductal hyperplasia (ADH/LG-DCIS), excluding micro-invasion, determining histologic subtypes and molecular phenotypes of breast cancer, and verifying breast as the primary site for metastatic carcinoma.

Immunohistochemistry-Market-Growth

In recent years, the use of IHC in the treatment of metastatic melanoma with the help of PD-L1 IHC immune therapy has revolutionized immuno-oncology. It is also used to predict the clinical response of two main cancers, breast and prostate carcinoma. Thus, demand for immunohistochemistry products will be propelled by the increasingly rising incidence and prevalence of cancer.

Increasing Geriatric Population to Majorly Stimulate the IHCMarket Growth

The spike in pharmaceutical approvals and the launch of technologically innovative immunohistochemistry solutions for disease detection is fueling the development of the IHC industry. For instance, p16 INK4a, a novel mouse monoclonal antibody intended for the qualitative identification of the p16 INK4a protein by IHC, was launched by U.S.-based Biocare Medical, LLC in September 2019.

In May 2019, Roche launched the latest Rabbit Monoclonal Primary Antibody VENTANA ROS1 (SP384) to detect ROS1-positive cancer cases. Moreover, in June 2019, the U.S. FDA approved the extended use of the PD-L1 IHC 22C3 pharmDx assay by Agilent Technologies to identify head and neck squamous cell carcinoma (HNSCC). This medicine is used in people undergoing medication with Keytruda from Merck and Co., Inc. (Pembrolizumab).

Furthermore, in 2018, F. Hoffmann-La Roche AG, one of the prominent players in the IHC industry, launched a new automated Ventana pan-tropomyosin receptor kinase (TRK) (EPR17341) assay. This recently introduced IHC assay is intended for the identification of TRK proteins in cancer patients. Besides, major players engaged in the production of IHC solutions are partnering with the manufacturers of prescription drugs to create and provide IHC diagnostic solutions for their immunotherapy.

In May 2018, for example, Roche, in partnership with Five Prime Therapeutics, Inc., developed IHC companion diagnostic assays to use with bemarituzumab, an investigational anti-FGFR2b antibody from Five Prime. It is projected in a way that such strategic strategies by key players might create a lucrative environment for the growth of the immunohistochemistry industry.

Global Immunohistochemistry Market: Segmentation

Antibodies to Lead the Product Segment

As a result of their ongoing use of IHC procedures for disease detection and drug testing, antibodies held the highest market share in 2019. Therapeutic monoclonal antibodies and antibody-related products, such as antibody fragments, Fc-fusion proteins, and antibody-drug conjugates have become the foremost product class in the industry.

Antibodies that recognize nuclear transcription factors are gradually finding applications in surgical pathology, such as determining possible anatomic sites for carcinoma of an unknown primary. Antibodies directed toward linear-restricted transcription factors are helpful and relatively specific diagnostic markers. Molecular genetic discoveries in the form of a single immunohistochemical stain might lead to better, inexpensive, and fast diagnostic tests.

Diagnostics Segment Accounted for Largest Share of Immunohistochemistry Market

The rising prevalence of cancer and the widespread use of IHC in the diagnosis of cancers, infectious diseases, cardiovascular diseases, and other diseases account for a significant share of this segment. For instance, the American Cancer Society estimated that more than 1.7 million new cancer cases were diagnosed in America in 2019.

According to Cancer Research U.K., every year 3,67,000 new cases of cancer are reported in the U.K. As a result, the rising prevalence of chronic diseases is projected to increase the demand for immunohistochemistry solutions that lead to market development. Besides, the increasing geriatric population, which is more vulnerable to infectious and other chronic diseases, and the growing number of diagnostic centers worldwide are few other factors driving the industry.

Technological advancements, such as automated sample preparation and digital pathology have added considerable value to the segmental growth. Moreover, the spike in the number of hospitals and clinical research laboratories has raised the need for diagnostics, bolstering the market.

Regional Overview

North-America-Lead-Immunohistochemistry-Market

The Escalating Prevalence of Bone-Related Disorders is the Key Factor Contributing to the North American IHC Market

North America is projected, to lead the overall market during the forecast period. Market growth is attributed to factors, such as the presence of leading players, the higher incidence of cancer and other chronic diseases in the country. For instance, as reported by the National Cancer Institute, under the National Institute of Health (NIH), in 2020, an estimated 1.8 million new cancer cases are expected to have been diagnosed within the United States, and 606,520 patients amongst them are anticipated to meet fatal consequences.

The vast number of patient pools, as per the figures, fuels demand growth in the sector. Besides, some of the drivers to accelerate market growth are favorable government policies and an increase in the number of research collaborations.

Asia-Pacific to Be One of the Emerging Hot Spots in the IHC Market in Coming Years

Asia-Pacific regions comprise mostly developing economies, such as Japan, China, India, Korea, and Australia that are constantly channeling efforts to develop sound and advance healthcare facilities. Thus, further with the rising prevalence of cancer, there have been more dedicated efforts towards cancer management. For instance, according to the Cancer Atlas, in 2018, 8.2 million cancer cases were diagnosed, which corresponds to 5.2 million deaths in the region.

The clinical development of immunotherapies has been boosted dramatically in the APAC IHC market over the past decade. According to a review published in the Journal for Immunotherapy of Cancer, as of December 2019, more than 6,000 clinical trials were currently active for evaluating Immuno-Oncology drugs, and about 40% of these trials were conducted at some stage in the Asia-Pacific region.

For instance, China, Australia, and South Korea are a few of the major locations for conducting such clinical trials, with 205, 189, and 76 facilities, respectively, that have been earlier used for FDA-approved Immunotherapies. Thus, these actors certainly impact market growth in the regional market positively.

Competitive Landscape

Companies operating in the market have introduced many strategic strategies that have strengthened their financial flexibility and helped them grow as key players in the market, such as alliances, acquisitions, and product launches.

Recent Developments

  • In 2019, Agilent obtained CE-IVD in Europe for its PD-L1 IHC 22C3 pharmDx assay to detect head and neck squamous cell carcinoma patients treated with KEYTRUDA.

Key Players

  • F. Hoffmann-La Roche Ltd.
  • Agilent Technologies, Inc.
  • Danaher
  • Bio SB, Inc.
  • Becton, Dickinson, and Company
  • Merck KGaA
  • PHC Holdings Corporation
  • Biocare Medical, LLC.
  • Others

Immunohistochemistry Market: Segmentation

By Product

  • Antibodies
    • Primary Antibodies
    • Secondary Antibodies
  • Reagents
    • Histological Stains
    • Blocking Sera and Reagents
    • Chromogenic Substrates
    • Fixation Reagents
    • Organic Solvents
    • Others
  • Equipment
  • Kits

By Application

  • Diagnostics
  • Drug Development & Testing
  • Other Applications

By Region

  • America
  • Europe
  • Asia-Pacific
  • The Middle-East and Africa

Frequently Asked Questions (FAQs)

Diagnostics Segment is expected to be the leading segment in Immunohistochemistry Market during the forecast period.
In 2019 Global Immunohistochemistry Market was valued at USD 1,800 million.
F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Danaher, Bio SB, Inc., Becton, Dickinson and Company, Merck KGaA, PHC Holdings Corporation, Biocare Medical, LLC are the top players in Immunohistochemistry Market.
North America is expected to hold the highest market share in Immunohistochemistry Market.
Rising incidence and prevalence of cancer, increasing geriatric population, rising number of diagnostic centers worldwide are the key factors expected to drive Immunohistochemistry Market during the forecast period.
The global immunohistochemistry market was estimated at USD 1,800 million in 2019 and is expected to grow at a 6.58% CAGR during the forecast period.
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times and included in every purchase.
We will send you an email with login credentials to access the report. You will also be able to download the pdf.
Basically, choose Pay by Purchase Order when you are checking out. We will connect with you via email to set up your order.

Immunohistochemistry (IHC) is a technique used to visualize and locate specific antigens in a tissue sample using antibodies conjugated to enzymes that catalyze reactions to form detectable compounds. The IHC methodology has undergone rapid transformative growth to cope with the growing demand for detailed and reliable data, leading to the emergence of sophisticated modifications that can collect more qualitative details. 

The global immunohistochemistry market was estimated at USD 1,800 million in 2019 and is expected to grow at a 6.58% CAGR during the forecast period.

Immunohistochemistry-Market

RisingIncidence and Prevalence of Cancer

Cancer is a public health burden, and the prevalence of cancer has grown exponentially globally across the years. According to the World Health Organization (WHO), cancer is the 2nd leading cause of death worldwide. It further states that an estimated 9.6 million death, i.e., in 2018, 1 in 6 deaths were reported due to cancer. As per GLOBOCAN, the prevalence of cancer was 43.8 million worldwide in 2018, and 9.6 million cancer deaths were registered in the same year.

In recent times, IHC has been most widely employed in oncology research to examine the cancer proteome. The key diagnostic applications of IHC include differentiating invasive carcinoma from pseudo-invasive lesions, normal ductal hyperplasia (UDH) from atypical ductal hyperplasia (ADH/LG-DCIS), excluding micro-invasion, determining histologic subtypes and molecular phenotypes of breast cancer, and verifying breast as the primary site for metastatic carcinoma.

Immunohistochemistry-Market-Growth

In recent years, the use of IHC in the treatment of metastatic melanoma with the help of PD-L1 IHC immune therapy has revolutionized immuno-oncology. It is also used to predict the clinical response of two main cancers, breast and prostate carcinoma. Thus, demand for immunohistochemistry products will be propelled by the increasingly rising incidence and prevalence of cancer.

Increasing Geriatric Population to Majorly Stimulate the IHCMarket Growth

The spike in pharmaceutical approvals and the launch of technologically innovative immunohistochemistry solutions for disease detection is fueling the development of the IHC industry. For instance, p16 INK4a, a novel mouse monoclonal antibody intended for the qualitative identification of the p16 INK4a protein by IHC, was launched by U.S.-based Biocare Medical, LLC in September 2019.

In May 2019, Roche launched the latest Rabbit Monoclonal Primary Antibody VENTANA ROS1 (SP384) to detect ROS1-positive cancer cases. Moreover, in June 2019, the U.S. FDA approved the extended use of the PD-L1 IHC 22C3 pharmDx assay by Agilent Technologies to identify head and neck squamous cell carcinoma (HNSCC). This medicine is used in people undergoing medication with Keytruda from Merck and Co., Inc. (Pembrolizumab).

Furthermore, in 2018, F. Hoffmann-La Roche AG, one of the prominent players in the IHC industry, launched a new automated Ventana pan-tropomyosin receptor kinase (TRK) (EPR17341) assay. This recently introduced IHC assay is intended for the identification of TRK proteins in cancer patients. Besides, major players engaged in the production of IHC solutions are partnering with the manufacturers of prescription drugs to create and provide IHC diagnostic solutions for their immunotherapy.

In May 2018, for example, Roche, in partnership with Five Prime Therapeutics, Inc., developed IHC companion diagnostic assays to use with bemarituzumab, an investigational anti-FGFR2b antibody from Five Prime. It is projected in a way that such strategic strategies by key players might create a lucrative environment for the growth of the immunohistochemistry industry.

Global Immunohistochemistry Market: Segmentation

Antibodies to Lead the Product Segment

As a result of their ongoing use of IHC procedures for disease detection and drug testing, antibodies held the highest market share in 2019. Therapeutic monoclonal antibodies and antibody-related products, such as antibody fragments, Fc-fusion proteins, and antibody-drug conjugates have become the foremost product class in the industry.

Antibodies that recognize nuclear transcription factors are gradually finding applications in surgical pathology, such as determining possible anatomic sites for carcinoma of an unknown primary. Antibodies directed toward linear-restricted transcription factors are helpful and relatively specific diagnostic markers. Molecular genetic discoveries in the form of a single immunohistochemical stain might lead to better, inexpensive, and fast diagnostic tests.

Diagnostics Segment Accounted for Largest Share of Immunohistochemistry Market

The rising prevalence of cancer and the widespread use of IHC in the diagnosis of cancers, infectious diseases, cardiovascular diseases, and other diseases account for a significant share of this segment. For instance, the American Cancer Society estimated that more than 1.7 million new cancer cases were diagnosed in America in 2019.

According to Cancer Research U.K., every year 3,67,000 new cases of cancer are reported in the U.K. As a result, the rising prevalence of chronic diseases is projected to increase the demand for immunohistochemistry solutions that lead to market development. Besides, the increasing geriatric population, which is more vulnerable to infectious and other chronic diseases, and the growing number of diagnostic centers worldwide are few other factors driving the industry.

Technological advancements, such as automated sample preparation and digital pathology have added considerable value to the segmental growth. Moreover, the spike in the number of hospitals and clinical research laboratories has raised the need for diagnostics, bolstering the market.

Regional Overview

North-America-Lead-Immunohistochemistry-Market

The Escalating Prevalence of Bone-Related Disorders is the Key Factor Contributing to the North American IHC Market

North America is projected, to lead the overall market during the forecast period. Market growth is attributed to factors, such as the presence of leading players, the higher incidence of cancer and other chronic diseases in the country. For instance, as reported by the National Cancer Institute, under the National Institute of Health (NIH), in 2020, an estimated 1.8 million new cancer cases are expected to have been diagnosed within the United States, and 606,520 patients amongst them are anticipated to meet fatal consequences.

The vast number of patient pools, as per the figures, fuels demand growth in the sector. Besides, some of the drivers to accelerate market growth are favorable government policies and an increase in the number of research collaborations.

Asia-Pacific to Be One of the Emerging Hot Spots in the IHC Market in Coming Years

Asia-Pacific regions comprise mostly developing economies, such as Japan, China, India, Korea, and Australia that are constantly channeling efforts to develop sound and advance healthcare facilities. Thus, further with the rising prevalence of cancer, there have been more dedicated efforts towards cancer management. For instance, according to the Cancer Atlas, in 2018, 8.2 million cancer cases were diagnosed, which corresponds to 5.2 million deaths in the region.

The clinical development of immunotherapies has been boosted dramatically in the APAC IHC market over the past decade. According to a review published in the Journal for Immunotherapy of Cancer, as of December 2019, more than 6,000 clinical trials were currently active for evaluating Immuno-Oncology drugs, and about 40% of these trials were conducted at some stage in the Asia-Pacific region.

For instance, China, Australia, and South Korea are a few of the major locations for conducting such clinical trials, with 205, 189, and 76 facilities, respectively, that have been earlier used for FDA-approved Immunotherapies. Thus, these actors certainly impact market growth in the regional market positively.

Competitive Landscape

Companies operating in the market have introduced many strategic strategies that have strengthened their financial flexibility and helped them grow as key players in the market, such as alliances, acquisitions, and product launches.

Recent Developments

  • In 2019, Agilent obtained CE-IVD in Europe for its PD-L1 IHC 22C3 pharmDx assay to detect head and neck squamous cell carcinoma patients treated with KEYTRUDA.

Key Players

  • F. Hoffmann-La Roche Ltd.
  • Agilent Technologies, Inc.
  • Danaher
  • Bio SB, Inc.
  • Becton, Dickinson, and Company
  • Merck KGaA
  • PHC Holdings Corporation
  • Biocare Medical, LLC.
  • Others

Immunohistochemistry Market: Segmentation

By Product

  • Antibodies
    • Primary Antibodies
    • Secondary Antibodies
  • Reagents
    • Histological Stains
    • Blocking Sera and Reagents
    • Chromogenic Substrates
    • Fixation Reagents
    • Organic Solvents
    • Others
  • Equipment
  • Kits

By Application

  • Diagnostics
  • Drug Development & Testing
  • Other Applications

By Region

  • America
  • Europe
  • Asia-Pacific
  • The Middle-East and Africa

Frequently Asked Questions (FAQs)

Diagnostics Segment is expected to be the leading segment in Immunohistochemistry Market during the forecast period.
In 2019 Global Immunohistochemistry Market was valued at USD 1,800 million.
F. Hoffmann-La Roche Ltd., Agilent Technologies, Inc., Danaher, Bio SB, Inc., Becton, Dickinson and Company, Merck KGaA, PHC Holdings Corporation, Biocare Medical, LLC are the top players in Immunohistochemistry Market.
North America is expected to hold the highest market share in Immunohistochemistry Market.
Rising incidence and prevalence of cancer, increasing geriatric population, rising number of diagnostic centers worldwide are the key factors expected to drive Immunohistochemistry Market during the forecast period.
The global immunohistochemistry market was estimated at USD 1,800 million in 2019 and is expected to grow at a 6.58% CAGR during the forecast period.
Call us, email us, or chat with us! We encourage your questions and feedback. We have a research concierge team available at all times and included in every purchase.
We will send you an email with login credentials to access the report. You will also be able to download the pdf.
Basically, choose Pay by Purchase Order when you are checking out. We will connect with you via email to set up your order.